The Only Cannabis Stock I Would Recommend Investors Consider Is a Newbie

With cannabis set to be legalized mid-October, investors everywhere who have not already invested in this sector are looking for entry points in hopes of striking it rich as this “green rush” continues full steam ahead. While I remain fervently in the camp of folks who believe the valuations of cannabis producers make absolutely no sense, I can understand the zest with which many believe in the underlying long-term argument. Instead of dissuading those from investing at these sky-high valuations, in this article I’m going to take a look at one cannabis producer who I believe is the “best of the bunch,” given future prospects and the fact that most producers are currently operating with negative earnings, making fundamental analysis a nightmare within this sector.

The Hydropothecary Corporation  (TSX:HEXO) is a relatively new addition to the Toronto Stock Exchange, and with a valuation of less than $1 billion (at the time of writing) is reminiscent of many of the Canadian cannabis giants who have grown to multi-billion dollar valuations in short order. With consolidation taking place at breakneck speed (and a number of deals in the billion-dollar-plus range), speculation as to the attractiveness of Hydropothecary as a takeover target may be warranted, given the company’s impressive operational performance to date.

Hydropothecary is based in Quebec, and has been touted as one of the leaders among its peers, with excellent production efficiency and production costs per gram of less than $1, allowing this company to compete on cost against even the leanest outfits operating today. Additionally, because the company operates in Quebec, Hydropothecary is likely to be able to keep its costs of production low for the foreseeable future, given the low cost of electricity in Quebec relative to other jurisdictions in Canada.

On the supply chain side of the equation, Hydropothecary has done a good job of securing demand for its end product once legalization hits. The company has signed an agreement with Société des alcools du Québec, which will last five years and virtually guarantee 200,000 kilograms of cannabis sales in that province, leading many to believe that Hydropothecary has the inside track to potentially monopolize or own a significant chunk, of Quebecois demand right out of the gate.

Bottom line

I don’t like to speculate, and I’m a fundamental analysis guy, so I still won’t invest any of my money in the cannabis industry anytime soon. That said, for investors who must do so, take a look at companies like Hydropothecary instead of the over-hyped and over-valued big names out there.

Stay Foolish, my friends.

Our #1 Stock to Buy in 2018 (and Beyond!)

When you buy heavily cyclical stocks at low prices… and then hold the shares until the cycle reaches its peak… you can make a very healthy profit.

Every investor knows that. But many struggle to identify the best opportunities.

Except The Motley Fool may have a plan to solve that problem! Our in-house analyst team has poured thousands of hours into their proprietary research – and this is the result.

Our top advisor Iain Butler has just identified his #1 stock to buy in 2018 (and beyond).

The last time this stock went from the low point of its cycle to the peak… shares shot from $12 to $40 inside of 4 years. That’s an 300%-plus return. And if you missed out on that ride, today might just be your second chance.

Click here to claim Iain’s new report, absolutely FREE!

Fool contributor Chris MacDonald has no position in any stocks mentioned in this article.

I consent to receiving information from The Motley Fool via email, direct mail, and occasional special offer phone calls. I understand I can unsubscribe from these updates at any time. Please read the Privacy Statement and Terms of Service for more information.